Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014, Article ID 279618, 9 pages
http://dx.doi.org/10.1155/2014/279618
Research Article

Identification of Levothyroxine Antichagasic Activity through Computer-Aided Drug Repurposing

1Medicinal Chemistry, Department of Biological Sciences, Faculty of Exact Sciences, National University of La Plata, 47 y 115, La Plata (B1900AJI) Buenos Aires, Argentina
2Instituto de Ciencia y Tecnología Dr. César Milstein (ICT Milstein), Argentinean National Council of Scientific and Technical Research (CONICET), Saladillo 2468, Ciudad Autónoma de Buenos Aires (C1440FFX), Argentina
3Instituto de Investigaciones Bioquímicas de Buenos Aires, Argentinean National Council of Scientific and Technical Research (CONICET), Avenida Patricias Argentinas 435, Ciudad Autónoma de Buenos Aires (C1405BWE), Argentina

Received 30 August 2013; Accepted 13 November 2013; Published 30 January 2014

Academic Editors: C. Mackereth, A. Paiardini, and X. Qiu

Copyright © 2014 Carolina L. Bellera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. R. Coura and S. L. De Castro, “A critical review on chagas disease chemotherapy,” Memorias do Instituto Oswaldo Cruz, vol. 97, no. 1, pp. 3–24, 2002. View at Google Scholar · View at Scopus
  2. Á. Moncayo and A. C. Silveira, “Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy,” Memorias do Instituto Oswaldo Cruz, vol. 104, supplement 1, pp. 17–30, 2009. View at Google Scholar · View at Scopus
  3. World Health Organization, Control of Chagas disease. Second report of the WHO Expert Committee, 2002.
  4. TDR, “Special Programme for Research and Training in tropical diseases), World Health Organiza-tion,” Research priorities for Chagas disease, human African trypanosomiasis and leishmaniasis, 2012.
  5. J. A. Urbina and R. Docampo, “Specific chemotherapy of Chagas disease: controversies and advances,” Trends in Parasitology, vol. 19, no. 11, pp. 495–501, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Murcia, B. Carrilero, and M. Segovia, “Limitations of currently available Chagas disease chemotherapy,” Revista Española De Quimioterapia, vol. 25, no. 1, pp. 1–3, 2012. View at Google Scholar
  7. F. Astelbauer and J. Walochnik, “Antiprotozoal compounds: state of the art and new developments,” International Journal of Antimicrobial Agents, vol. 38, no. 2, pp. 118–124, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Villalta, J. Scharfstein, A. W. Ashton et al., “Perspectives on the Trypanosoma cruzi-host cell receptor interactions,” Parasitology Research, vol. 104, no. 6, pp. 1251–1260, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Cuervo, G. B. Domont, and J. B. De Jesus, “Proteomics of trypanosomatids of human medical importance,” Journal of Proteomics, vol. 73, no. 5, pp. 845–867, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Sánchez-Sancho, N. E. Campillo, and J. A. Páez, “Chagas disease: progress and new perspectives,” Current Medicinal Chemistry, vol. 17, no. 5, pp. 423–452, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. V. G. Duschak and A. S. Couto, “An insight on targets and patented drugs for chemotherapy of chagas disease,” Recent Patents on Anti-Infective Drug Discovery, vol. 2, no. 1, pp. 19–51, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. V. G. Duschak and A. S. Couto, “Cruzipain, the major cysteine protease of Trypanosoma cruzi: a sulfated glycoprotein antigen as relevant candidate for vaccine development and drug target. A review,” Current Medicinal Chemistry, vol. 16, no. 24, pp. 3174–3202, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. G. C. Rodrigues, A. P. Aguiar, J. L. da Silva Gonçalves Vianez Jr., A. Macrae, A. C. N. de Melo, and A. B. Vermelho, “Peptidase inhibitors as a possible therapeutic strategy for chagas disease,” Current Enzyme Inhibition, vol. 6, no. 4, pp. 183–194, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Knox, V. Law, T. Jewison et al., “DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs,” Nucleic Acids Research, vol. 39, no. 1, pp. D1035–D1041, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. D. S. Wishart, C. Knox, A. C. Guo et al., “DrugBank: a comprehensive resource for in silico drug discovery and exploration,” Nucleic Acids Research, vol. 34, pp. D668–672, 2006. View at Google Scholar · View at Scopus
  16. F. Gan, B. Cao, D. Wu, Z. Chen, T. Hou, and X. Mao, “Exploring old drugs for the treatment of hematological malignancies,” Current Medicinal Chemistry, vol. 18, no. 10, pp. 1509–1514, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Talevi, E. A. Castro, and L. E. Bruno-Blanch, “Virtual screening: an emergent, key methodology for drug development in an emergent continent—a bridge towards patentability,” in Advances Methods and Applications in Chmoinformatics: Research Progress and New Applications, E. A. Castro and A. K. Haghi, Eds., pp. 229–246, IGI Global, Hershey, Pa, USA, 1st edition, 2011. View at Google Scholar
  18. S. N. Deftereos, C. Andronis, E. J. Friedla, A. Persidis, and A. Persidis, “Drug repurposing and adverse event prediction using high-throughput literature analysis,” Wiley Interdisciplinary Reviews: Systems Biology and Medicine, vol. 3, no. 3, pp. 323–334, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. A. Lussier and J. L. Chen, “The emergence of genome-based drug repositioning,” Science Translational Medicine, vol. 3, no. 96, Article ID 96ps35, 2011. View at Google Scholar
  20. S. Ekins, A. J. Williams, M. D. Krasowski, and J. S. Freundlich, “In silico repositioning of approved drugs for rare and neglected diseases,” Drug Discovery Today, vol. 16, no. 7-8, pp. 298–310, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Sardana, C. Zhu, M. Zhang, R. C. Gudivada, L. Yang, and A. G. Jegga, “Drug repositioning for orphan diseases,” Briefings in Bioinformatics, vol. 12, no. 4, pp. 346–356, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. M. P. Pollastri and R. K. Campbell, “Target repurposing for neglected diseases,” Future Medicinal Chemistry, vol. 3, no. 10, pp. 1307–1315, 2011. View at Google Scholar · View at Scopus
  23. J. M. dos Santos Filho, A. C. L. Leite, B. G. D. Oliveira et al., “Design, synthesis and cruzain docking of 3-(4-substituted-aryl)-1,2,4-oxadiazole-N-acylhydrazones as anti-Trypanosoma cruzi agents,” Bioorganic and Medicinal Chemistry, vol. 17, no. 18, pp. 6682–6691, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Z. Hernandes, M. M. Rabello, A. C. L. Leite et al., “Studies toward the structural optimization of novel thiazolylhydrazone- based potent antitrypanosomal agents,” Bioorganic and Medicinal Chemistry, vol. 18, no. 22, pp. 7826–7835, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. C. R. Rodrigues, T. M. Flaherty, C. Springer, J. H. McKerrow, and F. E. Cohen, “CoMFA and HQSAR of acylhydrazide cruzain inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 12, no. 11, pp. 1537–1541, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Huang, L. S. Brinen, and J. A. Ellman, “Crystal structures of reversible ketone-Based inhibitors of the cysteine protease cruzain,” Bioorganic and Medicinal Chemistry, vol. 11, no. 1, pp. 21–29, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Choe, L. S. Brinen, M. S. Price et al., “Development of α-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease,” Bioorganic and Medicinal Chemistry, vol. 13, no. 6, pp. 2141–2156, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Beaulieu, E. Isabel, A. Fortier et al., “Identification of potent and reversible cruzipain inhibitors for the treatment of Chagas disease,” Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 24, pp. 7444–7449, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. X. Du, E. Hansell, J. C. Engel, C. R. Caffrey, F. E. Cohen, and J. H. McKerrow, “Aryl ureas represent a new class of anti-trypanosomal agents,” Chemistry and Biology, vol. 7, no. 9, pp. 733–742, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Brak, P. S. Doyle, J. H. McKerrow, and J. A. Ellman, “Identification of a new class of nonpeptidic inhibitors of cruzain,” Journal of the American Chemical Society, vol. 130, no. 20, pp. 6404–6410, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. B. T. Mott, R. S. Ferreira, A. Simeonov et al., “Identification and optimization of inhibitors of trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB,” Journal of Medicinal Chemistry, vol. 53, no. 1, pp. 52–60, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. R. S. Ferreira, A. Simeonov, A. Jadhav et al., “Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors,” Journal of Medicinal Chemistry, vol. 53, no. 13, pp. 4891–4905, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. K. K. H. Ang, J. Ratnam, J. Gut et al., “Mining a cathepsin inhibitor library for new antiparasitic drug leads,” PLoS Neglected Tropical Diseases, vol. 5, no. 5, Article ID e1023, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. K. A. Scheidt, W. R. Roush, J. H. McKerrow, P. M. Selzer, E. Hansell, and P. J. Rosenthal, “Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors,” Bioorganic and Medicinal Chemistry, vol. 6, no. 12, pp. 2477–2494, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Golbraikh, M. Shen, Z. Xiao, Y.-D. Xiao, K.-H. Lee, and A. Tropsha, “Rational selection of training and test sets for the development of validated QSAR models,” Journal of Computer-Aided Molecular Design, vol. 17, no. 2–4, pp. 241–253, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Golbraikh and A. Tropsha, “Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection,” Molecular Diversity, vol. 5, no. 4, pp. 231–243, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Kawabata, “Build-up algorithm for atomic correspondence between chemical structures,” Journal of Chemical Information and Modeling, vol. 51, no. 8, pp. 1775–1782, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Hariharan, A. Janakiraman, R. Nilakantan et al., “MultiMCS: a fast algorithm for the maximum common substructure problem on multiple molecules,” Journal of Chemical Information and Modeling, vol. 51, no. 4, pp. 788–806, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. B. S. Everitt, S. Landau, M. Leese, and D. Stahl, “Optimization clustering techniques,” in Cluster Analysis, D. J. Balding, N. A. C. Cressie, G. M. Fitzmaurice et al., Eds., pp. 111–142, John Wiley & Sons, Chichester, UK, 5th edition, 2011. View at Google Scholar
  40. A. Talevi, C. L. Bellera, M. E. Di Ianni, P. R. Duchowicz, L. E. Bruno-Blanch, and E. A. Castro, “An integrated drug development approach applying topological descriptors,” Computers Aid Drug Design and Discovery, vol. 8, pp. 172–181, 2012. View at Google Scholar
  41. A. Yasri and D. Hartsough, “Toward an optimal procedure for variable selection and QSAR model building,” Journal of Chemical Information and Computer Sciences, vol. 41, no. 3–6, pp. 1218–1227, 2001. View at Google Scholar · View at Scopus
  42. J.-F. Truchon and C. I. Bayly, “Evaluating virtual screening methods: good and bad metrics for the “early recognition” problem,” Journal of Chemical Information and Modeling, vol. 47, no. 2, pp. 488–508, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Gálvez, R. García-Domenech, C. De Gregorio Alapont, J. V. De Julián-Ortiz, and L. Popa, “Pharmacological distribution diagrams: a tool for de novo drug design,” Journal of Molecular Graphics, vol. 14, no. 5, pp. 272–276, 1997. View at Publisher · View at Google Scholar · View at Scopus
  44. N. Triballeau, F. Acher, I. Brabet, J.-P. Pin, and H.-O. Bertrand, “Virtual screening workflow development guided by the “receiver operating characteristic” curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4,” Journal of Medicinal Chemistry, vol. 48, no. 7, pp. 2534–2547, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Labriola, M. Sousa, and J. J. Cazzulo, “Purification of the major cysteine proteinase (cruzipain) from Trypanosoma cruzi by affinity chromatography,” Biological Research, vol. 26, no. 1-2, pp. 101–107, 1993. View at Google Scholar · View at Scopus
  46. J. J. Cazzulo, M. C. Cazzulo Franke, J. Martinez, and B. M. Franke De Cazzulo, “Some kinetic properties of a cysteine proteinase (cruzipain) from Trypanosoma cruzi,” Biochimica et Biophysica Acta, vol. 1037, no. 2, pp. 186–191, 1990. View at Publisher · View at Google Scholar · View at Scopus
  47. J. J. Cazzulo, B. M. Franke de Cazzulo, J. C. Engel, and J. J. B. Cannata, “End products and enzyme levels of aerobic glucose fermentation in trypanosomatids,” Molecular and Biochemical Parasitology, vol. 16, no. 3, pp. 329–343, 1985. View at Google Scholar · View at Scopus
  48. M. Randić, “Similarity based on extended basis descriptors,” Journal of Chemical Information and Computer Science, vol. 32, pp. 686–692, 1992. View at Google Scholar · View at Scopus
  49. A. Jadhav, R. S. Ferreira, C. Klumpp et al., “Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease,” Journal of Medicinal Chemistry, vol. 53, no. 1, pp. 37–51, 2010. View at Publisher · View at Google Scholar · View at Scopus